



The Centre for Blood Research Seminar Series



Dr. Helen Burt

*Associate Vice President, Research & International
Head, Division of Drug Delivery
Angiotech Professor of Drug Delivery
(Centre for Drug Research and Development)*

Wednesday, May 22nd, 2013

LSC 3 - Life Sciences Centre
2350 Health Sciences Mall

12-1pm

*“Intravesicular nanoparticulate drug delivery systems
for application in bladder cancer”*

Bladder cancer is the fifth most common cancer in Canada and the incidence is increasing. Superficial disease is treated by surgical removal of tumors and the intravesical instillation of chemotherapy agents directly into the bladder via a catheter. However, the highly impermeable barrier presented by the superficial bladder mucosa seriously limit drug uptake and effectiveness of intravesical chemotherapy. Our work to develop very stable nanoparticulate hyperbranched polyglycerols (HPGs) modified to produce a hydrophobic core for drug loading (docetaxel) and surface amine groups to increase drug uptake, retention in bladder and provide greater efficacy in treating superficial bladder cancer will be discussed.

Sponsored by

CSL Behring
Biotherapies for Life™



a place of mind
THE UNIVERSITY OF BRITISH COLUMBIA



Canadian Blood Services
Société canadienne du sang